Stempoint Capital’s Arbutus Biopharma ABUS Stock Holding History

Stempoint Capital’s Portfolio ABUS Stock Details ABUS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-986,751	Closed	-$4.75M	–	84
2025 Q4	$4.75M	Buy	986,751 +781,363	+380%	+$3.51M	0.81%	43
2025 Q3	$932K	Buy	+205,388	New	+$754K	0.19%	63
2025 Q2	–	Sell	-467,882	Closed	-$1.63M	–	54
2025 Q1	$1.63M	Buy	+467,882	New	+$1.56M	0.52%	39

Other funds holding ABUS

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

TSC

Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return

WCM

Whitefort Capital Management New York $339M AUM 52.48% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

Stempoint Capital's ABUS Position: Q1 2026 in Review

Stempoint Capital sold out of Arbutus Biopharma (ABUS) in Q1 2026, closing a stake of 986,751 shares — an estimated $4.75M sold.

Stempoint Capital first reported a position in ABUS in Q1 2025 and held it in 3 quarters. The position peaked at $4.75M in Q4 2025. 167 funds tracked by Wall St. Rank hold ABUS as of Q1 2026.

Stempoint Capital reported no remaining Arbutus Biopharma position as of Q1 2026 after selling out during the quarter.
Stempoint Capital sold 986,751 Arbutus Biopharma shares in Q1 2026, an estimated $4.75M.
Stempoint Capital first reported a position in Arbutus Biopharma in Q1 2025 and held it in 3 quarters.
Stempoint Capital's Arbutus Biopharma position peaked at $4.75M in Q4 2025.
167 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q1 2026.

Based on Stempoint Capital's 13F filing for Q1 2026, filed 15 May 2026.